文献速递哮喘

噻托溴铵用于青少年重度症状性哮喘的随机对照试验

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.
PubMed 文献 · Eur Respir J · 2017-01-11

这项III期双盲平行组试验纳入392例12-17岁重度症状性哮喘患者,在ICS联合其他控制药物基础上加用每日一次噻托溴铵5μg或2.5μg或安慰剂治疗12周。5μg组峰值FEV1(0-3h)应答较安慰剂提高90mL(p=0.104),2.5μg组提高111mL(p=0.046);主要终点未达到,但肺功能与哮喘控制呈积极趋势,安全性与安慰剂相当。

要点

  • 每日一次噻托溴铵加用于ICS联合控制药物的青少年重度哮喘耐受性良好。
  • 主要疗效终点未达到,5μg组峰值FEV1改善90mL未达统计学显著。
  • 2.5μg组峰值FEV1较安慰剂显著改善111mL(p=0.046)。

核心结论

  • 每日一次噻托溴铵Respimat作为ICS联合一种或以上控制药物的附加治疗在青少年重度症状性哮喘中耐受性良好。
  • 主要疗效终点未达到,但观察到肺功能与哮喘控制的积极改善趋势。

研究设计与样本

  • III期双盲平行组随机对照试验(NCT01277523),392例12-17岁重度症状性哮喘患者随机接受每日一次噻托溴铵5μg、2.5μg或安慰剂,疗程12周。
  • 主要终点为治疗12周后给药后3小时内峰值FEV1(FEV1(0-3h))较基线的变化,关键次要终点为谷值FEV1。

主要发现

  • 噻托溴铵5μg组峰值FEV1(0-3h)应答较安慰剂数值提高90mL(p=0.104)。
  • 噻托溴铵2.5μg组峰值FEV1(0-3h)应答较安慰剂显著提高111mL(p=0.046)。
  • 两种剂量谷值FEV1应答及哮喘控制较安慰剂均呈数值改善。
  • 噻托溴铵安全性与耐受性与安慰剂相当。

临床怎么用

  • 在ICS联合其他控制药物治疗的青少年重度症状性哮喘中,可考虑加用每日一次噻托溴铵,但需注意主要疗效终点未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12-17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV1) within 3 h post-dosing (FEV1(0-3h)) and trough FEV1, respectively, after 12 weeks of treatment.Tiotropium 5 µg provided numerical improvements in peak FEV1(0-3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV1 response and asthma control were observed with both tiotropium doses, compared with placebo. The safety and tolerability of tiotropium were comparable with those of placebo.Once-daily tiotropium Respimat add-on to ICS plus one or more controller therapies in adolescents with severe symptomatic asthma was well tolerated. The primary end-point of efficacy was not met, although positive trends for improvements in lung function and asthma control were observed.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017. PMID: 27811070. doi:10.1183/13993003.01100-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。